MS-based approaches for studying the pharmacokinetics of protein drugs

Bioanalysis

Volumn 3, Issue 5, 2011, Pages 477-480

  Mesmin, Cédric ^a   Fenaille, François ^a   Ezan, Eric ^b   Becher, Fraņois ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b DIF   (France)

Author keywords

biologics; biotherapeutics; MS; pharmacokinetics; protein

Indexed keywords

ALPHA2 INTERFERON; DRUG; DRUG ANTIBODY; LOW MOLECULAR WEIGHT PROTEIN; RECOMBINANT DNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACCURACY; ADSORPTION; ANTIBODY AFFINITY; BINDING AFFINITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEIN PROTEIN INTERACTION; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; MOLECULAR WEIGHT; PROTEINS;

EID: 79953069684     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.21     Document Type: Review

References (22)

1. Chen G, Warrack BM, Goodenough AK, WeiH, Wang-Iverson DB, Tymiak AA. Characterization of protein therapeutics by mass spectrometry: Recent developments and future directions. Drug Discov. Today 16(1-2), 58-64 (2010).
2. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 134(5), 825-834 (2009).
3. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347(1-2), 3-11 (2009).
4. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today 15(1-2), 40-56 (2010).
5. van den Broek I, Sparidans RW,Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 872(1-2), 1-22 (2008).
6. Mesmin C, Dubois M, Becher F, Fenaille F, Ezan E. Liquid chromatography-tandem mass spectrometry assay for the absolute quantification of the expected circulating apelin peptides in human plasma. Rapid Commun. Mass Spectrom. 24(19), 2875-2884 (2010).
7. Murphy RE, Kinhikar AG, Shields MJ etal. Combined use of immunoassay and two-dimensional liquid chromatography-mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J. Pharm. Biomed. Anal. 53(3), 221-227 (2010).
8. Damen CW, Rosing H, Schellens JH, Beijnen JH. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. J. Pharm. Biomed. Anal. 46(3), 449-455 (2008).
9. Campbell JL, Le Blanc JC. Targeted ion parking for the quantitation of biotherapeutic proteins: Concepts and preliminary data. J. Am. Soc. Mass Spectrom. 21(12), 2011-2022 (2010).
10. Dupuis A, Hennekinne JA, Garin J, Brun V. Protein standard absolute quantification (PSAQ) for improved investigation of staphylococcal food poisoning outbreaks. Proteomics 8(22), 4633-4636 (2008).
11. Huang CJ, Lowe AJ, Batt CA. Recombinant immunotherapeutics: Current state and perspectives regarding the feasibility and market. Appl. Microbiol. Biotechnol. 87(2), 401-410 (2010).
12. Yang Z, Ke J, Hayes M, Bryant M, Tse FL. A sensitive and high-throughput LC-MS/MS method for the quantification of PEGylated-interferon-a2a in human serum using monolithic C18 solid phase extraction for enrichment. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(18-19), 1737-1742 (2009).
13. Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9(2), 82-90 (2004). (Pubitemid 38169532)
14. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 1(8), 1375-1388 (2009).
15. Heinig K , Wirz T. Determination of taspoglutide in human and animal plasma using liquid chromatography-tandem mass spectrometry with orthogonal column-switching. Anal. Chem. 81(10), 3705-3713 (2009).
16. Ji QC, Rodila R, El-Shourbagy TA. A sample preparation process for LC-MS/MS analysis of total protein drug concentrations in monkey plasma samples with antibody. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 847(2), 133-141 (2007). (Pubitemid 46331015)
17. Heudi O, Barteau S, Zimmer D etal. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008). (Pubitemid 351812775)
18. Neubert H, Grace C, Rumpel K, James I. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal. Chem. 80(18), 6907-6914 (2008).
19. Prechel MM, Orawski AT, Maggiora LL, Simmons WH. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J. Pharmacol. Exp. Ther. 275(3), 1136-1142 (1995). (Pubitemid 26130629)
20. Palazzuoli A, Antonelli G, Quatrini I, Nuti R. Natriuretic peptides in heart failure: Where we are, where we are going. Intern. Emerg. Med. 6(1), 63-68 (2010).
21. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. Invivo deamidation characterization of monoclonal antibody by LC-MS/MS. Anal. Chem. 77(5), 1432-1439 (2005). (Pubitemid 40327884)
22. van den Brock I, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 837(1-2), 49-58 (2006). (Pubitemid 43796292)